CN112512568A - 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法 - Google Patents

遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法 Download PDF

Info

Publication number
CN112512568A
CN112512568A CN201980046532.XA CN201980046532A CN112512568A CN 112512568 A CN112512568 A CN 112512568A CN 201980046532 A CN201980046532 A CN 201980046532A CN 112512568 A CN112512568 A CN 112512568A
Authority
CN
China
Prior art keywords
mva
cmv
nucleic acid
stability
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980046532.XA
Other languages
English (en)
Chinese (zh)
Inventor
费利克斯·乌索
唐·J·戴蒙德
海蒂·孔特雷拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN112512568A publication Critical patent/CN112512568A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980046532.XA 2018-05-11 2019-05-10 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法 Pending CN112512568A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670656P 2018-05-11 2018-05-11
US62/670,656 2018-05-11
PCT/US2019/031866 WO2019217922A1 (en) 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof

Publications (1)

Publication Number Publication Date
CN112512568A true CN112512568A (zh) 2021-03-16

Family

ID=68467105

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046532.XA Pending CN112512568A (zh) 2018-05-11 2019-05-10 遗传修饰的重组痘苗安卡拉(rmva)疫苗改善的稳定性及其制备方法

Country Status (5)

Country Link
US (1) US12054736B2 (https=)
EP (1) EP3790578A4 (https=)
JP (1) JP2021523712A (https=)
CN (1) CN112512568A (https=)
WO (1) WO2019217922A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
EP3529353A4 (en) 2016-10-19 2020-05-13 City of Hope USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY
KR20250005247A (ko) 2022-04-13 2025-01-09 시티 오브 호프 Cmv-hiv 특이적 키메라 항원 수용체 t 세포
WO2025184598A1 (en) * 2024-03-01 2025-09-04 City Of Hope Stable and immunogenic cmv vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110081708A1 (en) * 2009-10-07 2011-04-07 Genscript Holdings (Hong Kong) Limited Method of Sequence Optimization for Improved Recombinant Protein Expression using a Particle Swarm Optimization Algorithm
CN104838000A (zh) * 2012-07-27 2015-08-12 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
US20170246292A1 (en) * 2009-06-05 2017-08-31 City Of Hope Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835383B2 (en) 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
WO2018075813A1 (en) * 2016-10-19 2018-04-26 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170246292A1 (en) * 2009-06-05 2017-08-31 City Of Hope Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof
US20110081708A1 (en) * 2009-10-07 2011-04-07 Genscript Holdings (Hong Kong) Limited Method of Sequence Optimization for Improved Recombinant Protein Expression using a Particle Swarm Optimization Algorithm
CN104838000A (zh) * 2012-07-27 2015-08-12 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORINNA LA ROSA ET AL.: "MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults", BLOOD, vol. 129, no. 1, pages 114 - 125, XP086676883, DOI: 10.1182/blood-2016-07-729756 *
EDWIN R. MANUEL ET AL.: "Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses", VIROLOGY, vol. 403, no. 2, pages 155, XP027063382, DOI: 10.1016/j.virol.2010.04.015 *
Z WANG ET AL.: "A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector", VIROLOGY, vol. 277, no. 2, pages 379 *

Also Published As

Publication number Publication date
JP2021523712A (ja) 2021-09-09
EP3790578A4 (en) 2022-04-06
WO2019217922A1 (en) 2019-11-14
US20210062221A1 (en) 2021-03-04
EP3790578A1 (en) 2021-03-17
US12054736B2 (en) 2024-08-06

Similar Documents

Publication Publication Date Title
JP7554119B2 (ja) 共有抗原
JP7457733B2 (ja) 改変アデノウイルス
US12054736B2 (en) Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
JP7098330B2 (ja) Ｈｐｖワクチン
JP5123343B2 (ja) Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
JP7274223B2 (ja) マイクロサテライト不安定性（ｍｓｉ）癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン
US12064477B2 (en) HPV vaccine
Wang et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines
EA024749B1 (ru) Экспрессионный вектор со сниженным уровнем внутримолекулярной рекомбинации, содержащий гомологичные или гетерологичные нуклеотидные последовательности
CN114340661A (zh) Hiv抗原和mhc复合物
CN114657154B (zh) 一种羊传染性脓疱病毒减毒株的制备方法及其应用
KR20080021659A (ko) 백신 조성물
WO2016202828A1 (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
EP1890724A2 (en) Compositions for inducing an immune response
Wang et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector
US20230381299A1 (en) Vaccination of hematopoietic stem cell donors with cytomegalovirus triplex composition
KR20220119637A (ko) 치료용 백신을 위한 재조합 폭스바이러스를 설계하는 방법
RU2194075C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pTBI-HBsAg, СОДЕРЖАЩАЯ ХИМЕРНЫЙ ГЕН TBI-HBsAg ПОД КОНТРОЛЕМ ПРОМОТОРА p7.5K ВИРУСА ОСПОВАКЦИНЫ, И ШТАММ РЕКОМБИНАНТНОГО ВИРУСА ОСПОВАКЦИНЫ, ВЫЗЫВАЮЩИЙ ИММУННЫЙ ОТВЕТ ПРОТИВ ВИЧ И ГЕПАТИТА B ЧЕЛОВЕКА В ОРГАНИЗМЕ ЖИВОТНЫХ
CN121627808A (zh) Hpv-52型e6蛋白的特异性ctl表位肽及其应用
HK40082300A (en) Hpv vaccines
KR20240099203A (ko) 범코로나바이러스 백신
CN118302195A (zh) 泛冠状病毒疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210316

WD01 Invention patent application deemed withdrawn after publication